1Q FY2027 Cardinal Health, Inc. Earnings Conference - CARDINAL HEALTH INC

Financial Performance:

• Total revenue grew 5% year-over-year to $67.5 billion; consolidated gross profit increased 12% to $2.6 billion.
• Operating income rose 17% to $1 billion, driven by gross profit growth outpacing SG&A increases (9%).
• Diluted EPS grew 28% to $3.26; adjusted pre-tax cash flow totaled $1.6 billion, with year-end cash balance at $5.3 billion.
• Effective tax rate for Q1 was 18.5%; interest and other expenses were $67 million.
• Executed a $500 million accelerated share repurchase, reducing diluted weighted average shares outstanding to approximately 233 million.

Guidance and Future Outlook:

• Raised full-year non-GAAP EPS guidance to $12.80–$13.00 (previously $12.40–$12.60), reflecting 17–19% growth over ex-tariff fiscal 2026 EPS.
• Pharma segment profit guidance increased to 10–12% growth (previously 8–11%); revenue growth remains at 3–5%.
• "Other" growth businesses revenue guidance raised to 12–14% (previously 11–13%) and profit guidance to 17–20% (previously 15–18%).
• Global Medical Products and Distribution (GMPD) profit guidance remains $200–$220 million, though high petroleum costs may push results toward the low end.
• Earnings growth expected to moderate in Q2 and Q3 due to lapping of the Solaris acquisition and contract renewals, strengthening in Q4.
• Effective tax rate guidance lowered to 18.5–19.5% (previously 19–20%); adjusted free cash flow guidance remains $3.5–$4.0 billion.

Business Segments and Product Lines:

• Pharma: Revenue grew 6% to $62.6 billion; specialty sales surged 18% (high teens), driven by urology and oncology; generics volume grew above long-term targets.
• Renewals: Secured renewal with CVS Health through June 2032; renewed contracts now represent nearly two-thirds of enterprise revenue.
• GMPD: Revenue flat at $3.2 billion; profit of $33 million exceeded expectations; deployed 100+ autonomous robots in Dixon, CA; Cardinal Health brand grew in U.S. low-to-mid single digits.
• Other (Growth Businesses): Revenue up 7% to $1.8 billion; profit up 16% to $193 million; includes At-Home (Strive acquisition integration), Nuclear/Precision Health, and OptiFrate Logistics.
• Acquisitions & Investments: Solaris integration progressing on track; ADAPT deal anticipated post-calendar year; new 3PL facility in St. Louis launching by end of FY27.
• Biopharma Solutions: Secured new exclusive commercialization agreement in cell and gene market; Synexis patient hub on track to double supported therapies by FY28.

Market and Competitive Landscape:

• GLP-1 medications contributed ~500 bps of revenue growth in Pharma, partially offset by ~400 bps headwind from IRA WAC reductions.
• Strategic "Flywheel" effect demonstrated in urology, leveraging distribution, MSO, and nuclear capabilities to create cross-selling opportunities.
• Market remains fragmented in urology and at-home care, presenting consolidation opportunities for the company.
• Competitors (e.g., McKesson) pursue different strategic focuses; Cardinal Health differentiates via multi-specialty MSOs and unique growth business portfolios.
• Secular trends driving demand: shift to home-based care, complex medical innovation, and aging population.

Risks and Challenges:

• Regulatory: Ongoing impact of IRA WAC reductions and finalization of OPPS rules (340B reimbursement changes) could shift volume among providers.
• Operational: GMPD segment facing headwinds from high petroleum costs driven by the Iran conflict and modest commodity/transportation cost pressures.
• Macro/Political: Potential policy changes post-election; management maintains constructive engagement with policymakers on both sides.
• Integration: Risk associated with integrating acquisitions (Solaris, Strive) and realizing synergies without disrupting physician or patient experience.
• Currency: Foreign exchange acted as a headwind for GMPD during the quarter.

Management Commentary and Tone:

• Tone was highly confident and positive, emphasizing "broad-based growth," "disciplined execution," and "robust profit growth."
• Management highlighted the stability provided by long-term customer renewals (two-thirds of revenue secured) as a foundation for investment.
• Emphasis on "strengthening the core," scaling specialty, and improving GMPD through operational efficiency plans.
• Strong confidence in the "ecosystem" strategy, particularly in urology and oncology, noting a "rising tide" of demand across therapeutic areas.

Analyst Questions and Answers:

• Pharma Momentum: Confirmed underlying demand strength in specialty (urology/oncology) and generics (Red Oak partnership); Solaris integration on track with no new M&A contributions in Q1.
• Other Segment Growth: Driven by organic investments, acquisition synergies (Strive, ADAPT), and secular tailwinds; growth expected to accelerate in H2.
• Urology Strategy: Explained "1+1+1" value creation via ecosystem integration across distribution, MSOs, nuclear, and data services; pipeline for urologists is robust.
• Regulatory Impact (OPPS/340B): Expects volume shifts to benefit Cardinal Health due to diverse payer mix and ability to support providers; views provider harm as unintended by administration.
• Red Oak Partnership: Relationship is evergreen with continued value proposition; contract extension expected soon, potentially beyond 2029.
• Future M&A: Focus remains on "fragmented" sectors (specialty MSOs, Biopharma solutions, At-home) rather than a fourth business leg; disciplined capital allocation prioritizes organic CapEx ($700M) and share buybacks first.

Other Key Points:

• Capital allocation framework remains strict: $700M CapEx planned for supply chain, automation, and AI infrastructure; $500M share repurchase completed in Q1.
• Management reaffirmed commitment to "better access, lower costs, and continued innovation" aligning with bipartisan objectives.
• The Solaris acquisition will be fully lapped in Q2, influencing future quarter-over-quarter comparisons.
• AI-driven tools, such as route optimization for radio pharmacies, are expanding across the network, expected to reach all 130 sites by FY27.